查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1850471

骨关节炎治疗市场按治疗类型、给药途径、最终用户和分销管道划分－全球预测，2025-2032年

Osteoarthritis Therapeutics Market by Treatment Type, Route of Administration, End-User, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，骨关节炎治疗市场规模将达到 93.5 亿美元，复合年增长率为 7.68%。

关键市场统计数据
基准年 2024 51.7亿美元
预计年份：2025年 55.5亿美元
预测年份 2032 93.5亿美元
复合年增长率 (%) 7.68%

本书对当前骨关节炎治疗模式和不断发展的多学科治疗路径进行了简明扼要、权威的概述，旨在为相关人员的决策提供参考。

骨关节炎仍然是最常见的退化性关节疾病之一，因此临床上持续关注并进行多学科创新，旨在缓解疼痛、恢復功能并延缓或避免侵入性手术。近年来，治疗方法日趋融合，涵盖了从保守疗法和辅助疗法到先进的外科手术，这反映出以患者为中心的治疗理念正朝着个体化护理路径转变，力求在控制症状和长期保护关节之间取得平衡。临床医生、支付方和医疗保健提供者越来越重视多学科管理，将药物治疗、物理治疗、生活方式干预和选择性手术治疗相结合，以优化疗效并最大限度地减少副作用。

同时，技术赋能的医疗模式和数位疗法拓展了临床医生和患者可用的套件，实现了大规模的远端监测、依从性支持和復健。这些发展带来了新的机会和挑战，因为整个生态系统中的相关人员必须兼顾临床疗效、报销动态和病患偏好。重要的是，监管和安全考量将继续影响特定药物类别和关节内疗法的应用，因此需要强有力的证据支持和上市后监测。

随着医疗保健系统将重点放在以价值为导向的医疗服务和长期疗效上，骨关节炎治疗的策略规划需要对治疗路径、给药途径以及提供医疗服务的机构有深入的了解。本执行摘要总结了当前趋势、结构性变化和可操作的见解，旨在为製药、医疗技术和医疗服务机构的研发优先排序、产品组合管理和商业策略提供参考。

这是重塑骨关节炎治疗模式的关键曲折点，包括整合多模态治疗、生技药品、数位化復健和以价值主导的报销机制。

骨关节炎的治疗格局正在经历多项变革，这些变革正在重塑临床实践和商业策略。首先，治疗模式正明显转向多模态治疗，将针灸、按摩疗法和营养补充剂等辅助疗法与传统药物治疗和针对性手法治疗相结合。这种综合模式充分考虑了患者病情的多样性，并强调制定个人化的治疗方案，以减少对长期服用全身性止痛药物的依赖。

其次，生物製药和器械治疗方法的进步正在提升局部治疗的作用，包括复杂的关节内注射和微创手术。这些治疗方法旨在以更少的全身暴露缓解症状，其应用受到新兴临床证据、支付方政策以及门诊和日间手术能力的影响。第三，数位医疗和远距復健平台正在扩大患者获得物理治疗和自我管理计画的途径，改变患者参与和依从性的模式，并使医疗服务提供者能够将护理范围扩展到传统的实体诊疗之外。

第四，支付方和采购策略日益关注疗效和成本效益，奖励那些能够显着降低后续资源利用率的医疗模式，例如减少医院再入院和早期关节关节重建。最后，涵盖製药公司、医疗设备製造商、数位医疗供应商和专科诊所的跨产业合作正在推动新型商业伙伴关係和打包式医疗服务模式的出现。这些转变需要製定适应性策略，使临床证据的产生与新的医疗服务模式和不断发展的报销框架相契合。

评估2025年关税调整和贸易政策变化将如何改变骨关节炎治疗药物的供应链、采购经济效益和商业化时间表

近期有关关税和贸易的政策发展可能会对骨关节炎治疗格局产生重大影响，因为这会影响进口到美国的医疗设备、植入和某些药品原料的投入成本。对医疗设备和用于製造植入、关节镜检查设备以及某些注射药物的原材料征收更高的关税，可能会导致供应商的到岸成本上升，从而可能迫使製造商重新评估其筹资策略、供应商多元化和区域製造地。因此，在谈判设备采购和植入物合约时，医院和诊所可能会面临压力，需要争取更高的价值、延长采购週期，并在可能的情况下优先考虑国内替代方案。

此外，关税可能导致短期供应链波动，影响医院药房、零售店和销售骨关节炎治疗药物的线上药局的库存计划。供应商通常会在预期成本上升时调整定价策略、改变与经销商的谈判方式，或选择性地降低其产品组合的利润，这可能会影响产品的供应和促销投入。对于新药公司和小型製造商而言，关税主导的成本上涨可能会提高进入门槛并延缓商业化进程，尤其对于资本密集医疗设备的上市和依赖特殊组件的复杂生物製药。

为此，许多相关人员正在加速推进供应链韧性计划，包括近岸外包、双重采购和长期供应商协议，以降低关税波动带来的风险。医疗系统和集团采购组织的策略性应对措施包括情境规划，该规划整合了采购弹性、应对投入成本波动的合约条款以及在控製成本的同时维持医疗品质的临床替代路径。最终，2025年关税变化带来的累积影响凸显了製定综合商业和供应链策略的必要性，这些策略既能保障治疗药物和医疗设备的可及性，又能促进创新。

透过全面的细分，将治疗方式、给药途径、医疗机构环境和分销管道与临床和商业性应用驱动因素联繫起来，主导洞察。

细緻的市场区隔框架揭示了不同治疗类型、给药途径、最终用户和分销管道的独特需求驱动因素、护理路径和商业性需求。根据治疗类型，市场包括针灸、按摩疗法和营养补充剂等辅助疗法，以及皮质类固醇注射、透明质酸注射、非类固醇消炎剂和鸦片类药物等药物疗法。每种治疗方法的证据阈值、患者接受动态和报销情况各不相同，这些因素都会影响其普及曲线和医疗服务提供者的奖励。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 评估一种针对神经生长因子的新型单株抗体疗法在治疗骨关节炎疼痛的疗效
  • 引入再生医学方法，例如间质干细胞注射，用于治疗膝骨关节炎
  • 整合穿戴式感测器数据的数位健康平台对骨关节炎个人化治疗方案的影响
  • 骨关节炎治疗中关节内基因治疗产品的监管核准途径与安全性问题
  • 在骨关节炎早期阶段推广微骨折和支架式软骨修復技术
  • 为推进骨关节炎治疗决策中的真实世界证据，对患者报告结局指标的需求日益增长
  • 开发针对发炎细胞激素的新型小分子抑制剂，以延缓骨关节炎的进展

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 依治疗类型分類的骨关节炎治疗市场

  • 辅助疗法
    • 针刺
    • 按摩疗法
    • 营养补充品
  • 药物治疗
    • 皮质类固醇注射
    • 玻尿酸注射
    • 非类固醇消炎剂（NSAIDs）
    • 阿片类药物
  • 物理治疗
  • 外科手术
    • 关节镜
    • 关节重建
    • 截骨术
      • 股骨截骨术
      • 胫骨截骨术

9. 依给药途径分類的骨关节炎治疗市场

  • 注射
  • 口服
  • 外用
  • 经皮

第十章 依最终用户分類的骨关节炎治疗市场

  • 诊所
  • 医院
  • 復健中心

第十一章 骨关节炎治疗市场（依通路划分）

  • 医院药房
  • 网路药房
  • 零售药房

第十二章 各地区骨关节炎治疗市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 依组别分類的骨关节炎治疗市场

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 各国骨关节炎治疗市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • AbbVie Inc.
    • Amgen Inc.
    • AstraZeneca PLC
    • Bayer AG
    • Boehringer Ingelheim International GmbH
    • Cipla Ltd.
    • Eli Lilly and Company
    • Endo International plc
    • Ferring BV
    • Fidia Farmaceutici SpA
    • GlaxoSmithKline PLC
    • Johnson & Johnson Services Inc.
    • Merck & Co.
    • Pfizer Inc.
    • Sanofi SA
    • Sun Pharmaceutical Industries Ltd.
    • Teva Pharmaceutical Industries Ltd.
    • Viatris Inc.
Product Code: MRR-DD6333AE50BA

The Osteoarthritis Therapeutics Market is projected to grow by USD 9.35 billion at a CAGR of 7.68% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 5.17 billion
Estimated Year [2025] USD 5.55 billion
Forecast Year [2032] USD 9.35 billion
CAGR (%) 7.68%

A concise and authoritative overview of current osteoarthritis therapeutic paradigms and evolving multidisciplinary care pathways shaping stakeholder decision-making

Osteoarthritis remains one of the most prevalent degenerative joint disorders, driving sustained clinical attention and cross-sector innovation aimed at alleviating pain, restoring function, and delaying or avoiding invasive procedures. Recent years have seen a convergence of therapeutic approaches that span conservative complementary modalities through to advanced surgical interventions, reflecting a patient-centric shift toward personalized care pathways that balance symptom control with long-term joint preservation. Clinicians, payers, and providers increasingly emphasize multidisciplinary management, combining pharmacologic options with physical therapy, lifestyle interventions, and selective procedural therapies to optimize outcomes while minimizing adverse effects.

Concurrently, technology-enabled care models and digital therapeutics have expanded the toolkit available to clinicians and patients, enabling remote monitoring, adherence support, and rehabilitation at scale. These developments create new opportunities and complexities for stakeholders across the ecosystem, as they must reconcile clinical efficacy, reimbursement dynamics, and patient preferences. Importantly, regulatory scrutiny and safety considerations continue to shape the adoption of certain drug classes and intra-articular therapies, necessitating robust evidence generation and post-market surveillance.

As healthcare systems prioritize value-based care and longitudinal outcomes, strategic planning for osteoarthritis therapeutics requires nuanced understanding of treatment pathways, administration routes, and the providers who deliver care. This executive summary synthesizes current trends, structural shifts, and actionable insights that can inform R&D prioritization, portfolio management, and commercial strategies across pharmaceutical, medtech, and service delivery organizations.

Critical inflection points reshaping osteoarthritis treatment models including integration of multimodal care, biologics, digital rehabilitation, and value-driven reimbursement

The landscape of osteoarthritis therapeutics is undergoing several transformative shifts that are recalibrating clinical practice and commercial strategy. First, there is a clear reorientation toward multimodal care that integrates complementary therapies-such as acupuncture, massage therapy, and nutritional supplements-with traditional pharmacologic treatments and targeted procedural approaches. This integrated model acknowledges the heterogeneity of patient presentations and emphasizes individualized care plans that may reduce reliance on long-term systemic analgesics.

Second, advances in biologic and device-based interventions have elevated the role of localized therapies, including refined intra-articular injections and minimally invasive surgical techniques. These modalities aim to achieve symptom relief with lower systemic exposure, and their uptake is influenced by emerging clinical evidence, payer policies, and procedural capacity in outpatient and ambulatory settings. Third, digital health and tele-rehabilitation platforms are scaling access to supervised physical therapy and self-management programs, altering patient engagement and adherence dynamics and enabling providers to extend care beyond traditional brick-and-mortar encounters.

Fourth, payer and procurement strategies are increasingly focused on outcomes and cost-effectiveness, incentivizing care models that demonstrably reduce downstream resource utilization such as hospital readmissions or early joint replacement. Finally, cross-industry collaboration-spanning pharmaceuticals, medical device manufacturers, digital health vendors, and specialty clinics-is driving novel commercial partnerships and bundled care offerings. Together, these shifts demand adaptive strategies that align clinical evidence generation with novel delivery models and evolving reimbursement frameworks.

Assessing how tariff shifts and trade policy adjustments in 2025 can alter supply chains, procurement economics, and commercialization timelines across osteoarthritis therapeutics

Recent policy developments relating to tariffs and trade can exert meaningful influence on the osteoarthritis therapeutics landscape by affecting input costs for devices, implants, and certain pharmaceutical components imported into the United States. Increased duties on medical devices or raw materials used in manufacturing implants, arthroscopy equipment, and certain injectables can lead to higher landed costs for suppliers and may prompt manufacturers to reassess procurement strategies, supplier diversification, and regional manufacturing footprints. In turn, hospitals and clinics negotiating capital purchases and implant contracts may face pressure to extract greater value, extend procurement cycles, or prioritize domestically manufactured alternatives where available.

Moreover, tariffs can create short-term supply chain volatility that impacts inventory planning for hospital pharmacies, retail outlets, and online pharmacies that distribute osteoarthritis therapies. When suppliers anticipate cost headwinds, they often adjust pricing strategies, negotiate differently with distributors, or absorb margins selectively across portfolios, which can influence product availability and promotional investments. For innovators and smaller manufacturers, tariff-driven cost increases can heighten barriers to entry or slow commercialization timelines, particularly for capital-intensive device launches or complex biologic formulations that depend on specialized components.

In response, many stakeholders have accelerated supply chain resilience programs, including nearshoring, dual sourcing, and longer-term supplier agreements to mitigate exposure to tariff volatility. For health systems and group purchasing organizations, a strategic response includes scenario planning that integrates procurement flexibility, contract clauses addressing input-cost variability, and clinical substitution pathways that preserve care quality while managing cost. Ultimately, the cumulative impact of tariff changes in 2025 emphasizes the imperative for integrated commercial and supply chain strategies that protect access while sustaining innovation across therapeutics and devices.

Comprehensive segmentation-driven insights that map treatment modalities, administration routes, provider settings, and distribution channels to clinical and commercial adoption drivers

A nuanced segmentation framework illuminates distinct demand drivers, care pathways, and commercial imperatives across treatment type, route of administration, end-user, and distribution channel. Based on treatment type, the market comprises complementary therapies that include acupuncture, massage therapy, and nutritional supplements alongside drug therapy spanning corticosteroid injections, hyaluronic acid injections, non-steroidal anti-inflammatory drugs, and opioids; physical therapy modalities remain central to conservative management; and surgical solutions encompass arthroscopy, joint replacement, and osteotomy with femoral and tibial osteotomy subtypes that require distinct surgical expertise and implant considerations. Each of these treatment pathways has different evidence thresholds, patient acceptance dynamics, and reimbursement profiles, which in turn influence adoption curves and provider incentives.

Based on route of administration, therapies arrive via injectable, oral, topical, and transdermal pathways, with injectables attracting attention for their targeted delivery and potential for reduced systemic exposure, while oral and topical agents remain important for broad symptom management and ease of use. Based on end-user, clinics, hospitals, and rehabilitation centers each serve differentiated roles: clinics and outpatient centers emphasize access and conservative care delivery, hospitals provide surgical and acute interventions, and rehabilitation centers focus on intensive post-procedural recovery and functional restoration. Based on distribution channel, hospital pharmacies, online pharmacies, and retail pharmacies mediate how therapies reach patients, with each channel presenting unique considerations around inventory management, cold-chain logistics for certain injectables, patient counseling, and reimbursement coding.

Taken together, this segmentation underscores that product development, clinical trial design, and commercial planning must align with the practical realities of administration route, provider capabilities, and distribution pathways. Transitioning from clinical proof-of-concept to widespread adoption often requires tailored evidence packages, clinician education, and distribution agreements calibrated to the dominant channels serving target patient cohorts.

Regional strategic considerations tying patient demographics, reimbursement frameworks, and clinical infrastructure to differentiated adoption pathways across global markets

Regional dynamics shape access, adoption, and strategic priorities across the Americas, Europe, Middle East & Africa, and Asia-Pacific, each presenting distinct clinical infrastructures, reimbursement frameworks, and patient demographics. In the Americas, integrated health systems and private sector innovation support rapid uptake of minimally invasive procedures and advanced injectables, while payer negotiation and value-based contracting increasingly determine coverage decisions and formulary placement. Conversely, Europe, Middle East & Africa exhibit heterogeneous regulatory landscapes and procurement models; this region combines markets with high procedural capacity and sophisticated payers alongside settings where cost containment and access gaps emphasize conservative care and scalable rehabilitation solutions.

Asia-Pacific presents a diverse mix of highly innovative markets with strong manufacturing capabilities and rapidly growing clinical volumes alongside emerging healthcare systems investing in surgical capacity and rehabilitation services. Across all regions, demographic shifts toward aging populations and rising prevalence of osteoarthritis amplify demand for effective, durable interventions and scalable care pathways. Regional reimbursement nuances influence the prioritization of certain therapies, with some payers favoring interventions demonstrating demonstrable reductions in downstream surgical interventions and others prioritizing short-term cost containment.

Given these regional contours, manufacturers and service providers must tailor market entry strategies, evidence generation plans, and commercial models to local regulatory expectations, distribution norms, and provider reimbursement incentives. Strategic partnerships with regional distributors, capacity-building programs for surgeons and rehabilitation teams, and differentiated pricing strategies are critical levers to bridge clinical innovation with sustainable access across diverse geographies.

Competitive and innovation-focused intelligence revealing how clinical evidence, partnerships, and service models are redefining leadership in osteoarthritis therapeutics

Competitive dynamics within osteoarthritis therapeutics reflect a blend of established incumbents and agile challengers, with differentiation increasingly driven by the strength of clinical evidence, pathway integration capabilities, and service-enablement. Leading pharmaceutical and device organizations continue to invest in incremental innovation-refinements to injectables, implant materials, and surgical instrumentation-while newer entrants emphasize disruptive approaches such as regenerative therapies, novel biologics, and digitally enabled rehabilitation platforms. Partnerships and alliances between manufacturers, specialty clinics, and digital vendors are accelerating commercial reach and enabling bundled care propositions that align clinical outcomes with payer value goals.

R&D pipelines emphasize improved safety profiles, targeted delivery, and longer durability of effect, with clinical programs designed to generate real-world evidence that supports favorable reimbursement decisions. For surgical device makers and implant suppliers, manufacturing scale, cost-efficient supply chains, and service models that support surgeon training and OR efficiency have become competitive differentiators. At the same time, distributors and pharmacy channels are optimizing logistics and patient services to support therapy adherence and home-based care models.

Strategic M&A activity and licensing deals have favored entities that can complement broader portfolios with specialty devices, high-value biologics, or digital infrastructure that enhances long-term patient monitoring. For commercial leaders, the priority is to align product positioning with provider workflows and payer benchmarks, invest in clinician education to accelerate uptake, and deploy health economics evidence that articulates the value proposition in terms of patient outcomes and resource utilization.

Actionable strategic measures for manufacturers, providers, and payers to accelerate evidence-informed adoption, secure reimbursement, and strengthen supply chain resilience

Industry leaders should pursue a set of pragmatic, high-impact actions to navigate the current osteoarthritis therapeutics landscape and capture sustainable value. First, align clinical development with pragmatic endpoints that matter to payers and providers, including measures of functional improvement, durability of effect, and impact on downstream surgical rates, while integrating real-world evidence generation into post-approval plans to support reimbursement and uptake. Second, design commercialization strategies that match distribution channels and end-user needs: ensure hospital pharmacy readiness for specialty injectables, support online pharmacy patient services for outpatient therapies, and partner with clinics and rehabilitation centers to embed multimodal care pathways.

Third, invest in supply chain resilience and cost containment measures to mitigate exposure to tariff-related cost volatility and component shortages, including dual sourcing, regional manufacturing, and long-term supplier agreements. Fourth, develop bundled service offerings and clinician training programs that reduce barriers to adoption for novel surgical techniques and device platforms, and leverage digital rehabilitation and remote monitoring to extend patient engagement beyond the clinic. Fifth, cultivate payer engagement early to negotiate coverage pathways and value-based contracting that reflect long-term outcomes. Finally, prioritize cross-functional collaboration across R&D, commercial, regulatory, and supply chain teams to ensure coordinated launch execution and to adapt rapidly to evolving clinical evidence and reimbursement landscapes.

A rigorous, triangulated research methodology combining clinical evidence review, stakeholder interviews, and distribution channel analysis to underpin strategic recommendations

This analysis synthesizes insights derived from a triangulated research methodology combining structured literature review, expert interviews, and channel analysis to ensure both depth and practical relevance. The structured literature component encompassed peer-reviewed clinical studies, regulatory guidance, and specialty society recommendations to ground therapeutic claims in contemporary clinical evidence. Expert interviews with clinicians, procurement leaders, and commercial executives provided contextual understanding of adoption barriers, procedural trends, and payer negotiation dynamics, while channel analysis examined distribution nuances across hospital pharmacies, online pharmacies, and retail pharmacies to reflect the logistics and patient access implications of different therapies.

Where applicable, public regulatory filings and clinical trial registries informed assessment of pipeline priorities and safety considerations. The methodology emphasized cross-validation across data sources to enhance reliability and minimize bias, and findings were reviewed by practicing clinicians and industry experts to ensure practical applicability. Limitations of the research approach include heterogeneity in reporting standards across geographies and the evolving nature of tariff and trade policy, which necessitates ongoing monitoring. Nevertheless, the methodology provides a robust foundation for strategic decision-making by combining empirical clinical evidence, stakeholder perspectives, and operational channel insights.

Concluding synthesis that crystallizes strategic imperatives linking clinical evidence, distribution readiness, and operational resilience to long-term success in osteoarthritis care

In conclusion, osteoarthritis therapeutics occupy a dynamic intersection of clinical need, technological innovation, and evolving care delivery models. Stakeholders that successfully bridge robust clinical evidence with pragmatic commercial strategies-attuned to route of administration, provider settings, and distribution realities-will be best positioned to deliver differentiated value to patients and payers. The interplay of complementary therapies, targeted drug interventions, physical therapy, and surgical techniques underscores the necessity of integrated care pathways that are adaptable to patient heterogeneity and regional system constraints.

Supply chain resilience and strategic responses to tariff pressures will remain important operational considerations, particularly for devices and components with complex sourcing profiles. Competitive leadership will favor organizations that combine credible outcomes data, clinician engagement programs, and distribution capabilities across hospital, online, and retail channels. Ultimately, the most effective approaches are those that align product and service design with measurable improvements in patient function and quality of life while providing clear economic value to payers and health systems.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Evaluation of emerging monoclonal antibody therapies targeting nerve growth factor in osteoarthritis pain management
  • 5.2. Adoption of regenerative medicine approaches such as mesenchymal stem cell injections in knee osteoarthritis treatment landscape
  • 5.3. Impact of digital health platforms integrating wearable sensor data for personalized osteoarthritis treatment plans
  • 5.4. Regulatory approval pathways and safety concerns for intra-articular gene therapy products in osteoarthritis management
  • 5.5. Expansion of micro-fracture and scaffold-based cartilage repair techniques in early-stage osteoarthritis patients
  • 5.6. Rising demand for patient-reported outcome measures to drive real-world evidence in osteoarthritis therapeutic decision-making
  • 5.7. Development of novel small-molecule inhibitors targeting inflammatory cytokines in osteoarthritis progression

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Osteoarthritis Therapeutics Market, by Treatment Type

  • 8.1. Complementary Therapies
    • 8.1.1. Acupuncture
    • 8.1.2. Massage Therapy
    • 8.1.3. Nutritional Supplements
  • 8.2. Drug Therapy
    • 8.2.1. Corticosteroid Injections
    • 8.2.2. Hyaluronic Acid Injections
    • 8.2.3. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
    • 8.2.4. Opioids
  • 8.3. Physical Therapy
  • 8.4. Surgery
    • 8.4.1. Arthroscopy
    • 8.4.2. Joint Replacement
    • 8.4.3. Osteotomy
      • 8.4.3.1. Femoral Osteotomy
      • 8.4.3.2. Tibial Osteotomy

9. Osteoarthritis Therapeutics Market, by Route of Administration

  • 9.1. Injectable
  • 9.2. Oral
  • 9.3. Topical
  • 9.4. Transdermal

10. Osteoarthritis Therapeutics Market, by End-User

  • 10.1. Clinics
  • 10.2. Hospitals
  • 10.3. Rehabilitation Centers

11. Osteoarthritis Therapeutics Market, by Distribution Channel

  • 11.1. Hospital Pharmacies
  • 11.2. Online Pharmacies
  • 11.3. Retail Pharmacies

12. Osteoarthritis Therapeutics Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Osteoarthritis Therapeutics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Osteoarthritis Therapeutics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. AbbVie Inc.
    • 15.3.2. Amgen Inc.
    • 15.3.3. AstraZeneca PLC
    • 15.3.4. Bayer AG
    • 15.3.5. Boehringer Ingelheim International GmbH
    • 15.3.6. Cipla Ltd.
    • 15.3.7. Eli Lilly and Company
    • 15.3.8. Endo International plc
    • 15.3.9. Ferring B.V.
    • 15.3.10. Fidia Farmaceutici S.p.A
    • 15.3.11. GlaxoSmithKline PLC
    • 15.3.12. Johnson & Johnson Services Inc.
    • 15.3.13. Merck & Co.
    • 15.3.14. Pfizer Inc.
    • 15.3.15. Sanofi S.A.
    • 15.3.16. Sun Pharmaceutical Industries Ltd.
    • 15.3.17. Teva Pharmaceutical Industries Ltd.
    • 15.3.18. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY END-USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. OSTEOARTHRITIS THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. OSTEOARTHRITIS THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. OSTEOARTHRITIS THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COMPLEMENTARY THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COMPLEMENTARY THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COMPLEMENTARY THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COMPLEMENTARY THERAPIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COMPLEMENTARY THERAPIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COMPLEMENTARY THERAPIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COMPLEMENTARY THERAPIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COMPLEMENTARY THERAPIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ACUPUNCTURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ACUPUNCTURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ACUPUNCTURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ACUPUNCTURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ACUPUNCTURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ACUPUNCTURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY MASSAGE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY MASSAGE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY MASSAGE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY MASSAGE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY MASSAGE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY MASSAGE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY CORTICOSTEROID INJECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY CORTICOSTEROID INJECTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY CORTICOSTEROID INJECTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY CORTICOSTEROID INJECTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY CORTICOSTEROID INJECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY CORTICOSTEROID INJECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY HYALURONIC ACID INJECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY HYALURONIC ACID INJECTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY HYALURONIC ACID INJECTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY HYALURONIC ACID INJECTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY HYALURONIC ACID INJECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY HYALURONIC ACID INJECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OPIOIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OPIOIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OPIOIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OPIOIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OPIOIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OPIOIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY PHYSICAL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY PHYSICAL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY PHYSICAL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY PHYSICAL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY PHYSICAL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY PHYSICAL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SURGERY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SURGERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SURGERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SURGERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SURGERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SURGERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SURGERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ARTHROSCOPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ARTHROSCOPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ARTHROSCOPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ARTHROSCOPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ARTHROSCOPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ARTHROSCOPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY JOINT REPLACEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY JOINT REPLACEMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY JOINT REPLACEMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY JOINT REPLACEMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY JOINT REPLACEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY JOINT REPLACEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OSTEOTOMY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OSTEOTOMY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OSTEOTOMY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OSTEOTOMY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OSTEOTOMY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OSTEOTOMY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OSTEOTOMY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OSTEOTOMY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY FEMORAL OSTEOTOMY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY FEMORAL OSTEOTOMY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY FEMORAL OSTEOTOMY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY FEMORAL OSTEOTOMY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY FEMORAL OSTEOTOMY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY FEMORAL OSTEOTOMY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TIBIAL OSTEOTOMY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TIBIAL OSTEOTOMY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TIBIAL OSTEOTOMY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TIBIAL OSTEOTOMY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TIBIAL OSTEOTOMY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TIBIAL OSTEOTOMY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TRANSDERMAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TRANSDERMAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TRANSDERMAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TRANSDERMAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY REHABILITATION CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY REHABILITATION CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY REHABILITATION CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY REHABILITATION CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY REHABILITATION CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY REHABILITATION CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. AMERICAS OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 180. AMERICAS OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 181. AMERICAS OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 182. AMERICAS OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 183. AMERICAS OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COMPLEMENTARY THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 184. AMERICAS OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COMPLEMENTARY THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 185. AMERICAS OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2018-2024 (USD MILLION)
  • TABLE 186. AMERICAS OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2025-2032 (USD MILLION)
  • TABLE 187. AMERICAS OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2024 (USD MILLION)
  • TABLE 188. AMERICAS OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SURGERY, 2025-2032 (USD MILLION)
  • TABLE 189. AMERICAS OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OSTEOTOMY, 2018-2024 (USD MILLION)
  • TABLE 190. AMERICAS OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OSTEOTOMY, 2025-2032 (USD MILLION)
  • TABLE 191. AMERICAS OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 192. AMERICAS OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 193. AMERICAS OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 194. AMERICAS OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 195. AMERICAS OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 196. AMERICAS OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 197. NORTH AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. NORTH AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 200. NORTH AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COMPLEMENTARY THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 202. NORTH AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COMPLEMENTARY THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 203. NORTH AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2018-2024 (USD MILLION)
  • TABLE 204. NORTH AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2025-2032 (USD MILLION)
  • TABLE 205. NORTH AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2024 (USD MILLION)
  • TABLE 206. NORTH AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SURGERY, 2025-2032 (USD MILLION)
  • TABLE 207. NORTH AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OSTEOTOMY, 2018-2024 (USD MILLION)
  • TABLE 208. NORTH AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OSTEOTOMY, 2025-2032 (USD MILLION)
  • TABLE 209. NORTH AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 210. NORTH AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 212. NORTH AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 214. NORTH AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. LATIN AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. LATIN AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 218. LATIN AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 219. LATIN AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COMPLEMENTARY THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 220. LATIN AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COMPLEMENTARY THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2018-2024 (USD MILLION)
  • TABLE 222. LATIN AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2025-2032 (USD MILLION)
  • TABLE 223. LATIN AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2024 (USD MILLION)
  • TABLE 224. LATIN AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SURGERY, 2025-2032 (USD MILLION)
  • TABLE 225. LATIN AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OSTEOTOMY, 2018-2024 (USD MILLION)
  • TABLE 226. LATIN AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OSTEOTOMY, 2025-2032 (USD MILLION)
  • TABLE 227. LATIN AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 228. LATIN AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 229. LATIN AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 230. LATIN AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 231. LATIN AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 232. LATIN AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COMPLEMENTARY THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COMPLEMENTARY THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2018-2024 (USD MILLION)
  • TABLE 240. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SURGERY, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OSTEOTOMY, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OSTEOTOMY, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPE OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPE OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COMPLEMENTARY THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COMPLEMENTARY THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SURGERY, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OSTEOTOMY, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OSTEOTOMY, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 269. MIDDLE EAST OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. MIDDLE EAST OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. MIDDLE EAST OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 272. MIDDLE EAST OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 273. MIDDLE EAST OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COMPLEMENTARY THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 274. MIDDLE EAST OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COMPLEMENTARY THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 275. MIDDLE EAST OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2018-2024 (USD MILLION)
  • TABLE 276. MIDDLE EAST OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2025-2032 (USD MILLION)
  • TABLE 277. MIDDLE EAST OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2024 (USD MILLION)
  • TABLE 278. MIDDLE EAST OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SURGERY, 2025-2032 (USD MILLION)
  • TABLE 279. MIDDLE EAST OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OSTEOTOMY, 2018-2024 (USD MILLION)
  • TABLE 280. MIDDLE EAST OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OSTEOTOMY, 2025-2032 (USD MILLION)
  • TABLE 281. MIDDLE EAST OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 282. MIDDLE EAST OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 283. MIDDLE EAST OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 284. MIDDLE EAST OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 285. MIDDLE EAST OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 286. MIDDLE EAST OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 287. AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 288. AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 289. AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 290. AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 291. AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COMPLEMENTARY THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 292. AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COMPLEMENTARY THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 293. AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2018-2024 (USD MILLION)
  • TABLE 294. AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2025-2032 (USD MILLION)
  • TABLE 295. AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2024 (USD MILLION)
  • TABLE 296. AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SURGERY, 2025-2032 (USD MILLION)
  • TABLE 297. AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OSTEOTOMY, 2018-2024 (USD MILLION)
  • TABLE 298. AFRICA O